MaxCyte (MXCT) (MXCT)
:MXCT
Want to see MXCT full AI Analyst Report?
MXCT Stock Chart & Stats
$1.21
$0.04(3.42%)
―
--
Day’s Range― - ―
52-Week Range$0.64 - $2.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$129.62M
Enterprise Value$132.55M
Total Cash (Recent Filing)$14.56M
Total Debt (Recent Filing)$17.49M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Aug 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding107,121,670
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)0.96
Price to Sales (P/S)4.99
P/FCF Ratio-4.56
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue4.11
Enterprise Value/Gross Profit5.09
Enterprise Value/Ebitda-3.68
Forecast
1Y Price Target
$4.00Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$30.83M
Bulls Say, Bears Say
Bulls Say
Strong Cash Position And Low LeverageA large cash balance with no debt provides multi-quarter financial flexibility to fund operations, support product launches, and absorb timing of SPL milestones. Over a 2–6 month horizon this materially lowers near-term refinancing risk and enables tactical investments or share repurchases.
Recurring Consumables-driven Platform ModelMaxCyte’s business mixes instrument placements with proprietary consumables, creating a durable recurring revenue stream as customers scale experiments and manufacturing. This installed-base economics supports long-term revenue visibility and high gross margin capture as utilization grows.
Large SPL Partner Pipeline And Milestone UpsideAn extensive SPL roster with multiple clinical programs embeds MaxCyte’s platform into partners’ development paths. Realizable milestones and royalties offer high-leverage, non-linear upside that can accelerate revenue and margins as programs advance toward registrational and commercial inflection points.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow indicates the business is consuming cash to sustain operations and growth. Even with a large cash stockpile, ongoing burn increases the likelihood of future financing if milestones or core revenue recovery are delayed, pressuring strategic optionality.
Declining Core Revenue And Weakened DemandA sizable drop in core revenue—driven by softer instrument placements, license receipts and processing/assembly volumes—signals underlying demand and commercial execution challenges. If sustained, this undermines the recurring consumables base and compresses the path to sustainable profitability.
Nasdaq Minimum-bid Noncompliance And Market-access RiskA formal Nasdaq noncompliance notice creates a persistent capital-markets overhang that can constrain equity access, deter institutional investors, and reduce share liquidity. Over the medium term this raises fundraising costs and strategic friction if additional capital or transactional flexibility is needed.
MaxCyte News
MXCT FAQ
What was MaxCyte (MXCT)’s price range in the past 12 months?
MaxCyte (MXCT) lowest stock price was $0.64 and its highest was $2.40 in the past 12 months.
What is MaxCyte (MXCT)’s market cap?
MaxCyte (MXCT)’s market cap is $129.62M.
When is MaxCyte (MXCT)’s upcoming earnings report date?
MaxCyte (MXCT)’s upcoming earnings report date is Aug 12, 2026 which is in 72 days.
How were MaxCyte (MXCT)’s earnings last quarter?
MaxCyte (MXCT) released its earnings results on May 12, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.076 by $0.036.
Is MaxCyte (MXCT) overvalued?
According to Wall Street analysts MaxCyte (MXCT)’s price is currently Undervalued.
Does MaxCyte (MXCT) pay dividends?
MaxCyte (MXCT) does not currently pay dividends.
What is MaxCyte (MXCT)’s EPS estimate?
MaxCyte (MXCT)’s EPS estimate is -0.09.
How many shares outstanding does MaxCyte (MXCT) have?
MaxCyte (MXCT) has 107,121,670 shares outstanding.
What happened to MaxCyte (MXCT)’s price movement after its last earnings report?
MaxCyte (MXCT) reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.076. Following the earnings report the stock price went up 24.088%.
Which hedge fund is a major shareholder of MaxCyte (MXCT)?
Currently, no hedge funds are holding shares in MXCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MaxCyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (― Downside)
$4.00 (― Downside)
Hedge Fund Trend
Decreased
By 15.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.3K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-22.03%
Trailing 12-Months
Asset Growth
-15.43%
Trailing 12-Months
Company Description
MaxCyte (MXCT)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
MXCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational and strategic positives — including a strong cash position, meaningful OpEx reductions, a $3.0M SPL milestone in Q1, early product traction (ExPERT DTX and SeQure), and a $10M share repurchase authorization — against near-term commercial headwinds, notably a 25% decline in core revenue and weaker PA and license receipts driven by customer inventory management and discontinued programs. Management reiterated full-year guidance while taking a conservative stance on additional 2026 milestones; they emphasized stability in the late-stage cell and gene therapy market, confidence in the pipeline, and expectations for core revenue growth later in the year. Overall, the results reflect transitionary near-term pressure but solid financial flexibility and promising product/partner catalysts that could drive recovery and growth over the medium term.View all MXCT earnings summariesMXCT Stock 12 Month Forecast
Average Price Target
$4.00
Ownership Overview
2.02% Insiders
10.56% Mutual Funds
26.81% Other Institutional Investors
52.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---